A guide to the steps companies can take to evaluate their device developer’s HFE process.
The device should be carefully matched to end users, rather than be an afterthought.
Via partnerships with pharmaceutical companies, Insulet expands its platform technology past insulin delivery.
The company will invest €13 million in the facility, which will make drug-coated balloons for peripheral artery disease.
Researchers say the technology enables a high drug load and consistent drug release profile.